Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TELO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.26% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.56M USD | Price to earnings Ratio - | 1Y Target Price 15.25 |
Price to earnings Ratio - | 1Y Target Price 15.25 | ||
Volume (30-day avg) 171914 | Beta - | 52 Weeks Range 2.73 - 9.39 | Updated Date 04/1/2025 |
52 Weeks Range 2.73 - 9.39 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -250.96% | Return on Equity (TTM) -810.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 96233196 | Price to Sales(TTM) - |
Enterprise Value 96233196 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 29762700 | Shares Floating 17618311 |
Shares Outstanding 29762700 | Shares Floating 17618311 | ||
Percent Insiders 34.17 | Percent Institutions 12.08 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Telomir Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on developing and commercializing Telomir-1, a small molecule compound targeting telomere length. Founded relatively recently, it is dedicated to addressing age-related diseases through telomere biology.
Core Business Areas
- Drug Development: Research and development of Telomir-1 for various age-related indications.
Leadership and Structure
The company is led by a management team with expertise in pharmaceutical development. The organizational structure is typical of a small, research-focused biotech company.
Top Products and Market Share
Key Offerings
- Telomir-1: Telomir-1 is the company's lead drug candidate, targeting telomere length maintenance. It is currently in pre-clinical stage. There is not market share or number of users or revenue at this moment. Competitors are those involved in longevity research, including but not limited to companies exploring gene therapies and senolytics
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There is increasing interest in longevity and age-related disease research. Early-stage companies often face challenges in securing funding and navigating regulatory hurdles.
Positioning
Telomir Pharmaceuticals is positioned as an early-stage company focused on telomere biology. Its competitive advantage depends on the efficacy and safety of Telomir-1.
Total Addressable Market (TAM)
The TAM for age-related disease therapies is potentially very large, estimated to be in the billions of dollars. Telomir's positioning within the TAM depends on the success of Telomir-1 in clinical trials and its ability to address specific age-related conditions. It could be a niche therapy or a broader treatment depending on its profile.
Upturn SWOT Analysis
Strengths
- Focus on a novel biological pathway (telomeres)
- Potential for addressing unmet needs in age-related diseases
- Dedicated management team
Weaknesses
- Early-stage company with limited resources
- High risk of drug development failure
- Reliance on a single drug candidate
Opportunities
- Positive pre-clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- CRIS
- ABBV
- LLY
- NVO
Competitive Landscape
Telomir Pharmaceuticals faces significant competition from larger, established pharmaceutical companies. Its advantage lies in its focus on a specific biological pathway and its potential to develop a novel therapy.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A - Early stage company
Future Projections: Future growth will depend on the success of Telomir-1 in clinical trials and its ability to secure funding and partnerships.
Recent Initiatives: Recent initiatives likely include progressing Telomir-1 through pre-clinical studies and seeking funding opportunities.
Summary
Telomir Pharmaceuticals is an early-stage pharmaceutical company focusing on telomere biology with a high-risk, high-reward profile. Its future depends on the success of its lead drug candidate, Telomir-1, in pre-clinical and clinical trials. While there are no revenues, the focus on the novel biological pathway of targeting telomere length could be a competitive advantage. It must secure further funding to continue its research and development efforts.
Similar Companies
- CRIS
- ABBV
- LLY
- NVO
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telomir Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2024-02-09 | Chairman of the Board & CEO Mr. Erez Aminov | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telomirpharma.com |
Full time employees - | Website https://telomirpharma.com | ||
Telomir Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory mechanism. The company is developing Telomir 1, an oral small molecule metal ion regulator designed to extend telomere caps; maintain cellular balance; and combat oxidative stress that drives aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 helps protect against age-related conditions, including Progeria, a rare genetic disorder that causes rapid aging in children; Wilson's disease, a genetic disorder leading to toxic copper buildup in the body; and Age-related Macular Degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.